Breaking News Instant updates and real-time market news.

RHHBY

Roche

$28.68

-0.16 (-0.55%)

12:36
03/21/18
03/21
12:36
03/21/18
12:36

FDA approves Genentech's Lucentis

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration approved the Lucentis 0.3 mg prefilled syringe as a new method of administering the medicine to treat all forms of diabetic retinopathy. In April 2017, Lucentis 0.3 mg became, and remains, the first and only FDA-approved medicine to treat all forms of diabetic retinopathy in people with or without diabetic macular edema, a complication of the eye disease that causes swelling in the back of the eye. Diabetic retinopathy is the leading cause of blindness among working age adults and affects nearly 7.7M people in the U.S. The Lucentis 0.3 mg PFS is now the first syringe prefilled with an anti-vascular endothelial growth factor agent FDA-approved to treat both diabetic retinopathy and DME.

  • 30

    May

RHHBY Roche
$28.68

-0.16 (-0.55%)

02/08/18
02/08/18
DOWNGRADE

Neutral
Regeneron downgraded to Neutral ahead of Roche readout at BTIG
As previously reported, BTIG analyst Dane Leone downgraded Regeneron (REGN) to Neutral from Buy, stating that he is optimistic that Roche's (RHHBY) coming read-out of the BOULEVARD study may show encouraging clinical results on Feb 13 to support a pivotal effort and may show VEGF + ANG2 inhibition may provide incremental benefits over VEGF therapy alone in DME and potentially wetAMD. He also noted that REGN1979 bi-specific has shown limited efficacy in patients with Agg-NHL.
02/12/18
LEER
02/12/18
NO CHANGE
Target $502
LEER
Outperform
Data from Regeneron Eylea competitors should lift some overhang, says Leerink
Leerink analyst Geoffrey Porges says that the "confusing and somewhat lackluster data" presented over the weekend for Eylea's theoretical competitors should lift some of the overhang that Regeneron's stock has suffered from over the last 6 months. Novartis' (NVS) brolucizumab pivotal trial is confusing, and the data incomplete, and the analyst has serious doubts about the drug's approvability. Secondly, the addition of Ang2 inhibition to VEGF inhibition, while theoretically intriguing, has so far been of modest benefit despite Roche's (RHHBY) posturing, he contends. Porges reiterates an Outperform rating and $502 price target on Regeneron's shares.
02/27/18
02/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Stryker (SYK) upgraded to Neutral from Sell at Citi by analyst Amit Hazan, who believes supply issues at Zimmer Biomet (ZBH) could drive share gains for Stryker. 2. Chipotle (CMG) upgraded to Outperform from Neutral at Baird by analyst David Tarantino, who cited its new CEO and the potential for the company to demonstrate better sales/traffic momentum over the next 12-24 months. He believes it will support investor sentiment given the opportunity for the company to deliver strong earnings power if unit volumes begin to recover. 3. Itron (ITRI) upgraded to Buy from Hold at Cannacord Genuity by analyst Chip Moore, who said he has increased conviction in the company's forward earnings power and finds current share levels a "very compelling" entry point. He notes the stock is down 10% since the SilverSpring Networks deal announcement back in September. Moore's views the combination as compelling and has increased confidence in cost saving potential post close. 4. Winnebago (WGO) upgraded to Outperform from Market Perform at BMO Capital by analyst Gerrick Johnson, who said that the RV market growth -- currently in its 9th year -- will continue at a 10% pace, adding that the company's growth can outgain the competition because of its "operating improvement, enhanced product offering, and emerging trade-up cycle from first time buyers." The analyst also noted that Winnebago will benefit from lower corporate taxes while its stock trades at "significant" valuation discount. 5. Exelixis (EXEL) upgraded to Outperform from Perform at Oppenheimer by analyst Leah Rush Cann. The analyst is now applying a valuation methodology for profitable companies to Exelixis, since the company turned profitable for the full-year 2017. She expects Exelixis will continue to develop its commercial drugs, Cabometyx and Cometriq, while its partner Genentech (RHHBY) will continue to develop Cotellic. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/09/18
PIPR
03/09/18
NO CHANGE
Target $170
PIPR
Overweight
Piper confident in Alexion positioning after Roche trial halt
Piper Jaffray analyst Christopher Raymond keeps an Overweight on Alexion Pharmaceuticals (ALXN) following news of a temporary trial halt for Roche's (RHHBY) Soliris/AXLN1210 challenger RO7112689 in Europe. While a bit early to write off RO7112689 as a competitive threat, the halt highlights the strength of the clinical profile for ALXN1210 and Soliris, Raymond tells investors in a research note. He remains remains confident in Alexion's positioning and bullish on the shares with a $170 price target.

TODAY'S FREE FLY STORIES

NDX

Nasdaq 100 Index

08:16
04/25/18
04/25
08:16
04/25/18
08:16
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

$18.06

-2.74 (-13.17%)

08:15
04/25/18
04/25
08:15
04/25/18
08:15
Hot Stocks
Zai Lab, Entasis announce exclusive license agreement in Asia-Pacific »

Entasis Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

AMGN

Amgen

$171.91

-2.75 (-1.57%)

08:15
04/25/18
04/25
08:15
04/25/18
08:15
Recommendations
Amgen analyst commentary  »

Amgen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 17

    May

  • 22

    May

  • 28

    May

ZLAB

Zai Lab

$18.06

-2.74 (-13.17%)

08:14
04/25/18
04/25
08:14
04/25/18
08:14
Hot Stocks
Zai Lab, Entasis announce license agreement for ETX2514 in Asia-Pacific region »

Entasis Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

WYNN

Wynn Resorts

$189.70

-3.54 (-1.83%)

08:13
04/25/18
04/25
08:13
04/25/18
08:13
Hot Stocks
Wynn Resorts sees opening Boston Harbor project in mid-2019 »

With its earnings report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

DARE

Dare Bioscience

$0.82

0.0054 (0.67%)

08:13
04/25/18
04/25
08:13
04/25/18
08:13
Hot Stocks
Dare Bioscience, Juniper emter into exclusive worldwide license agreement »

Dare Bioscience announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$189.70

-3.54 (-1.83%)

08:12
04/25/18
04/25
08:12
04/25/18
08:12
Hot Stocks
Wynn Resorts CEO says Boston project not for sale »

Wynn Resorts CEO Matt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

TWTR

Twitter

$30.48

-0.74 (-2.37%)

08:12
04/25/18
04/25
08:12
04/25/18
08:12
Hot Stocks
Twitter CEO says soliciting external experts to improve health of service »

CEO Jack Dorsey said on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

AVXS

AveXis

$210.76

0.77 (0.37%)

08:11
04/25/18
04/25
08:11
04/25/18
08:11
Hot Stocks
AveXis announces first patient dosed in Phase 3 trial of AVXS-101 »

AveXis announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

PHM

PulteGroup

$29.66

0.84 (2.91%)

08:11
04/25/18
04/25
08:11
04/25/18
08:11
Upgrade
PulteGroup rating change  »

PulteGroup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

HESM

Hess Midstream Partners

$19.49

-0.92 (-4.51%)

08:11
04/25/18
04/25
08:11
04/25/18
08:11
Earnings
Hess Midstream Partners reaffirms FY18 net income view $335M-$360M »

Reaffirms FY18 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CUE

Cue Biopharma

$13.45

-0.03 (-0.22%)

08:11
04/25/18
04/25
08:11
04/25/18
08:11
Hot Stocks
Cue Biopharma appoints Anish Suri, Ph.D. as Chief Scientific Officer »

Cue Biopharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$201.16

-14.855 (-6.88%)

08:10
04/25/18
04/25
08:10
04/25/18
08:10
Recommendations
3M analyst commentary  »

3M price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 18

    May

  • 30

    May

CEMI

Chembio Diagnostics

$7.80

-0.05 (-0.64%)

08:09
04/25/18
04/25
08:09
04/25/18
08:09
Hot Stocks
Chembio Diagnostics, LumiraDx enter collaboration for POC diagnostic tests »

Chembio Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 29

    May

EW

Edwards Lifesciences

$134.63

-2.59 (-1.89%)

08:09
04/25/18
04/25
08:09
04/25/18
08:09
Downgrade
Edwards Lifesciences rating change  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

INSE

Inspired Entertainment

$4.85

-0.4 (-7.62%)

08:08
04/25/18
04/25
08:08
04/25/18
08:08
Hot Stocks
Inspired Entertainment signs games content agreement with Novomatic »

Inspired Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$42.96

-2.44 (-5.37%)

08:08
04/25/18
04/25
08:08
04/25/18
08:08
Recommendations
Mercury Systems analyst commentary  »

Mercury Systems weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

HESM

Hess Midstream Partners

$19.49

-0.92 (-4.51%)

08:08
04/25/18
04/25
08:08
04/25/18
08:08
Earnings
Hess Midstream Partners reports Q1 EPS 30c, consensus 28c »

Reports Q1 revenue $157M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TWTR

Twitter

$30.48

-0.74 (-2.37%)

08:08
04/25/18
04/25
08:08
04/25/18
08:08
Hot Stocks
Twitter: 'Privacy is a fundamental right for everyone we serve on our service' »

Comment taken from the Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

APH

Amphenol

$82.76

-1.645 (-1.95%)

08:08
04/25/18
04/25
08:08
04/25/18
08:08
Hot Stocks
Amphenol increases dividend 21% to 23c per share, approves $2B buyback plan »

Amphenol's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 17

    May

LKFN

Lakeland Financial

$48.90

0.46 (0.95%)

08:08
04/25/18
04/25
08:08
04/25/18
08:08
Earnings
Lakeland Financial reports Q1 EPS 71c, consensus 70c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$64.14

-0.25 (-0.39%)

08:07
04/25/18
04/25
08:07
04/25/18
08:07
Periodicals
Icahn says Washington not for him, hasn't spoken with Trump in months »

"Neither I nor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLX

Hologic

$38.62

0.18 (0.47%)

08:07
04/25/18
04/25
08:07
04/25/18
08:07
Hot Stocks
Hologic: FDA grants premarket approval for ThinPrep Integrated Imager »

Hologic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 08

    May

  • 12

    Jun

CPF

Central Pacific

$31.00

0.63 (2.07%)

08:07
04/25/18
04/25
08:07
04/25/18
08:07
Earnings
Central Pacific reports Q1 EPS 48c, consensus 31c »

Reports Q1 NII $42.32M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

APH

Amphenol

$82.76

-1.645 (-1.95%)

08:06
04/25/18
04/25
08:06
04/25/18
08:06
Earnings
Amphenol raises FY18 adjusted EPS view to $3.49-$3.55 from $3.39-$3.47 »

FY18 EPS consensus $3.46.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.